Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual resu
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:6/29/2015)... June 30, 2015 Mordor Intelligence presents ... Primary Packaging Material (Plastic, Glass, Paper, Metal) - ByType of ... Pouches, Syringes, Tubes, Vials, Sachets) - By Geographical Region ( ... Asia Pacific , Latin America ... Africa ) - discussing Industry Value Chain Analysis, ...
(Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
(Date:6/29/2015)... Minn. , June 29, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... it has commenced an underwritten public offering of units. ... stock, Series A warrants to purchase common stock and ... purchase of units in the offering would result in ...
Breaking Medicine Technology:Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
... June 21, 2011 Enox Biopharma, Inc. CEO, John C. ... Innovation Conference on Wednesday, June 22 at 12:15 AM EST. ... in Boston. The IN3 East meeting, hosted ... The meeting is designed to provide exposure and constructive interaction ...
... MOUNT LAUREL, N.J., June 21, 2011 ImpactRx, ... on physician prescribing behavior announced that Kjell Nygren, ... Analytical Services.  Kjell will strengthen the company,s position ... address clients, needs for better understanding the effectiveness ...
Cached Medicine Technology:Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
(Date:6/30/2015)... , ... June 30, 2015 , ... Trenton Health Team ... the first Medicaid Accountable Care Organizations (ACO) in the State, serving the greater Trenton ... , The Trenton Health Team ACO draws on the collaborative structure of THT, bringing ...
(Date:6/30/2015)... New Port Richey, FL (PRWEB) , ... June 30, 2015 , ... ... heroin use nearly doubled from 2007 to 2013 while heroin-related deaths more than tripled ... their greatest drug threat (1). Novus Medical Detox Center , a leading Florida-based ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Broadway by ... which features multiple patient and family member testimonials. Medicare rated the care center as ... plans to use the video to give future patients a firsthand look at the ...
(Date:6/30/2015)... Scotch Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Dental Techniques, they will be wowed with the incredible care that they receive and ... quality care for their patients; but now they are proud to offer the same ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... general manager of HRA Healthcare Research & Analytics , a consultative healthcare ... Associates, Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and ...
Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3
... NHS treatments has been accused of placing money before ... anti-cancer drug. <BR.,Patients suffering from cancer linked to asbestos ... name is pemetrexed disodium, after a study ... (NICE). ,The group analyzed the cost effectiveness of ...
... a report of the Washington Post, the department of health of ... subject every district resident, between 14years and 84years, ... antibodies. , The launching of the campaign, to be ... with the 12th annual National HIV Testing Day. ,Gregg ...
... last year, surgeons from Australia had performed the first ever-triple ... Hospital had carried out the surgery on a 33-year-old woman, ... Myles was reported to be on her deathbed due to ... ,She was diagnosed when she was 19, with a rare ...
... lacking a gene for normal immune functioning found to ... //liver and spleen - a new study finds. ... pathogen called Leishmania donovani, affects certain internal organs. People ... often affected by this infectious disease through the bite ...
... department today advised people to take precautionary measures in view ... and jaundice during summer. // ,The people have ... minutes and wash raw vegetables and fruit thoroughly before eating, ... has also advised people to wash hands with soap after ...
... Lek has said that the country could be restricting a ... This is being done for the fear that most potential ... infertile couples seeking medical treatment to have babies, but they ... that such procedures would only be allowed if 'a particular ...
Cached Medicine News:Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 3
The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
For the quantitative in vitro determination of Triglycerides in serum and plasma....
Medicine Products: